Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review

Justin Famoso, Gerald Lemole, Srinath Sundararajan, Baldassarre Stea

Research output: Contribution to journalArticle

Abstract

Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70%). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of >138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.

Original languageEnglish (US)
Pages (from-to)1148-1153
Number of pages6
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2019
Externally publishedYes

Fingerprint

Melanoma
Radiation
Pineal Gland
Survival
Residual Neoplasm
Rare Diseases
Disease-Free Survival
Disease Progression
Radiotherapy
Immunohistochemistry
Drug Therapy
Therapeutics
pembrolizumab

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma : A Case Report and Literature Review. / Famoso, Justin; Lemole, Gerald; Sundararajan, Srinath; Stea, Baldassarre.

In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 17, No. 10, 01.10.2019, p. 1148-1153.

Research output: Contribution to journalArticle

@article{acb6635143dd49f0ab550c94f5266e9f,
title = "Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review",
abstract = "Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70{\%}). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of >138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.",
author = "Justin Famoso and Gerald Lemole and Srinath Sundararajan and Baldassarre Stea",
year = "2019",
month = "10",
day = "1",
doi = "10.6004/jnccn.2019.7336",
language = "English (US)",
volume = "17",
pages = "1148--1153",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma

T2 - A Case Report and Literature Review

AU - Famoso, Justin

AU - Lemole, Gerald

AU - Sundararajan, Srinath

AU - Stea, Baldassarre

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70%). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of >138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.

AB - Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70%). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of >138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.

UR - http://www.scopus.com/inward/record.url?scp=85072954381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072954381&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.7336

DO - 10.6004/jnccn.2019.7336

M3 - Article

C2 - 31590158

AN - SCOPUS:85072954381

VL - 17

SP - 1148

EP - 1153

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 10

ER -